Category Reports Biotech

Immutep is no longer a simple high-upside oncology story. It is now a damaged but still very much alive recovery case. The flagship Phase III dream in first-line NSCLC broke hard, the stock’s credibility took a real hit, and the market had to reprice the company in a hurry. But the company did not come out of that blow as an empty shell. It still has cash, still has surviving clinical branches, still has outside validation, and now has a fresh FDA orphan drug designation in soft tissue sarcoma that puts a real regulatory spotlight back on eftilagimod alfa.

Plenty of companies announce an earnings date. Very few deserve a dedicated article just because of that. What makes this group worth watching is that each company is walking into its next business update with a specific pressure point that matters more than the quarter itself.

Teva entered 2026 with a more credible transformation story than it had just a few years ago. The company reported 2025 revenue of $17.3 billion, up 4% year over year, marking its third consecutive year of growth. That matters because Teva is still carrying the legacy of a global generics business, but the mix is gradually shifting toward innovative medicines, biosimilars, and pipeline assets that management believes can support more durable long-term growth.

Hoth added another mechanistic layer to its HT-VA obesity / fatty-liver narrative today, with gene-level data showing reduced Srebf1 and increased Pparα in a VA / Emory CRADA model. That strengthens the scientific story, but it does not remove the core market question: can HOTH turn early preclinical promise and encouraging HT-001 oncology-supportive data into a financed, executable development path without crushing dilution?

Allogene Therapeutics has spent years trying to prove that allogeneic, off-the-shelf CAR-T can become something more than a clever scientific pitch. Today’s ALPHA3 interim futility analysis does not finish that argument, but it materially changes the tone of it.

Daraxonrasib just turned a long-building RAS story into a frontline market conversation. The key question is no longer whether Revolution Medicines has a serious pancreatic program. The question now is how large the platform can become, how quickly the company can convert today’s Phase 3 win into approvals, and how much upside still remains after a violent breakout.

Two biotech names, two very different clinical stories, one synchronized release window. IDEAYA and Spyre are both scheduled to report clinically meaningful updates on Monday, April 13, 2026 at 8:00 a.m. ET, creating an unusually clean side-by-side setup for traders watching biotech volatility, narrative rotation, and cross-flow behavior before the actual readouts hit.

TLX101-Px accepted by FDA; PDUFA goal date set for September 11, 2026
The clearest near-term regulatory focal point is now TLX101-Px, Telix’s brain cancer imaging candidate for recurrent or progressive glioma. Management has also kept a H1 2026 target for the TLX250-Px / Zircaix BLA resubmission after working through the post-CRL comparability package.

Cingulate is one of those micro-cap biotech stories where the entire equity case has compressed into a narrow window: one lead ADHD asset, one PDUFA date, a visible commercialization build-out, and a very real dilution overhang.

This is our first full Merlintrader deep dive on CLDX. The core of the story is simple: Celldex is being valued primarily as a barzolvolimab company, but the real debate is whether barzolvolimab can move from an unusually strong phase 2 setup into a durable commercial immunology franchise across CSU, inducible urticarias and potentially additional inflammatory skin diseases.

Vera has moved from a pure data story into a real pre-commercial FDA story. The old thesis was about whether atacicept could produce strong enough renal data to justify a major rerating. The April 2026 thesis is narrower and more demanding: can Vera convert strong upstream biology, a clean Phase 3 interim package and a differentiated at-home profile into approval, a credible first launch, and a durable place in an IgAN market that is no longer empty?

VRCA is no longer a simple one-product dermatology story. The company now combines a real commercial base in YCANTH, a large common-warts expansion opportunity with unusually helpful cost-sharing economics, and a basal cell carcinoma asset in VP-315 that continues to add regulatory and scientific credibility. The stock still carries the usual small-cap biotech risks, but the narrative is broader and more interesting than the older “just molluscum and financing stress” version.